Synonyms: β-artemether | beta-artemether
artemether is an approved drug (FDA (2009) in combination with lumefantrine)
Compound class:
Synthetic organic
Comment: Artemether is a semisynthetic derivative of artemisinin, a natural product isolated from the qinghao or sweet wormwood plant (Artemisia annua). Synthesis yields two crystalline anomers, α- and β-artemether, the latter predominates and is marginally more active [2].
Artemether is a prodrug that is converted to the active metabolite artenimol (dihydroartemisinin). The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. |
|
No information available. |
Summary of Clinical Use |
Artemether is on the World Health Organization's Model List of Essential Medicines. The 2009 US FDA approval for this compound is in combination with lumefantrine (trade name Coartem®) and is one of the artemisinin-based combination therapies (ACTs) recommended in the World Health Organization's Guidelines for the treatment of malaria [4]. The European Medicines Agency (EMA) granted orphan designation for the combined formulation in 2010 (link to the EMA Orphan Designation record here). The WHO guidelines also recommend intramuscular injection of artemether for the treatment of severe malaria if artesunate is not available [3]. The link to extended ADME data provided below is for the combined formulation with lumefantrine. |
External links |
For extended ADME data see the following: Drugs.com |